The objective of the Ohio State University (OSU) postdoctoral oncology training program is to provide a focused perspective and state-of-the-art research training in cancer biology and aspects of cancer treatment to postdoctoral fellows selected from motivated and gifted M.D., D.O., DVM, or Ph.D. candidates who have strong interests in cancer research and are committed to careers in patient-oriented cancer research. The rationale of the program is that advances in cancer therapy and prevention are most likely to come from physician- scientists and basic scientists who have trained in a research environment that fosters collaboration between clinical and laboratory investigators focused on the pursuit of specific research goals. The participating faculty consists of the program director, chair of the advisory committee, director/assistant director of education, mentors and contributing faculty. The program design consists of formal academic courses, seminars and journal clubs to provide trainees with an overview of cancer biology and a broad cancer research orientation. Each trainee will perform independent research projects in a mentor's laboratory. In the 43-year history of this training grant at OSU, 154 postdoctoral students have been trained in basic and translational cancer research by a cadre of outstanding NIH funded participating faculty. Of these 154 trainees, ~85% have engaged in academic or industrial scientific pursuits for all or a significant portion of their careers after leaving the fellowship program, and this success rate has been sustained over the past 15 years of Dr. Caligiuri's tenure as PI of this award. The research areas and scientific disciplines encompassed by the 47 mentors and the 11 contributing faculty are represented by their individual affiliations with one of the six OSU Comprehensive Cancer Center (CCC) Research Programs: Molecular Biology and Cancer Genetics, Experimental Therapeutics, Immunology, Molecular Carcinogenesis and Chemoprevention, Oncogenic Virus and Cancer Control. Mentors and contributing faculty are all NIH/NCI/DOD/ACS-funded basic scientists and physician- investigators that have developed a network of collaborative interactions within the CCC allowing the trainee to be exposed to a multiple research perspectives and expertise. The T32 faculty participate with trainees in joint conferences which further enhance appreciation of different research approaches. The anticipated levels of experience of eligible postdoctoral candidates are two to seven years, and the duration of the proposed training is two years. This competitive renewal application seeks continued support again for 8 trainees each year for 5 years.

Public Health Relevance

of this grant proposal to Public Health is that advances in cancer therapy and prevention are most likely to come from physician-investigators and basic life scientists who have trained in a research environment that fosters collaboration between clinical and laboratory investigators focused on the pursuit of specific research goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA009338-36
Application #
8742746
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1978-07-01
Project End
2019-06-30
Budget Start
2014-07-09
Budget End
2015-06-30
Support Year
36
Fiscal Year
2014
Total Cost
$464,434
Indirect Cost
$35,833
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Halley, Patrick D; Lucas, Christopher R; McWilliams, Emily M et al. (2016) Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model. Small 12:308-20
Yoo, Ji Young; Jaime-Ramirez, Alena Cristina; Bolyard, Chelsea et al. (2016) Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy. Clin Cancer Res 22:5265-5276
Byrd, John C; Harrington, Bonnie; O'Brien, Susan et al. (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 374:323-32
Brathwaite, Shayna; Rock, Jonathan; Yearsley, Martha M et al. (2016) Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. Ann Surg Oncol 23:2281-6
Harrington, Bonnie K; Gardner, Heather L; Izumi, Raquel et al. (2016) Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS One 11:e0159607
Mundy-Bosse, Bethany L; Scoville, Steven D; Chen, Li et al. (2016) MicroRNA-29b mediates altered innate immune development in acute leukemia. J Clin Invest 126:4404-4416
Rogers, Kerry A; Byrd, John C (2016) Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver. Cancer Cell 29:3-4
Kearney, Cathal J; Lucas, Christopher R; O'Brien, Fergal J et al. (2016) DNA Origami: Folded DNA-Nanodevices That Can Direct and Interpret Cell Behavior. Adv Mater 28:5509-24
Brathwaite, Shayna; Kuhrt, Maureen; Yu, Lianbo et al. (2015) Retrospective Evaluation of Laparoscopic Versus Open Hartmann's Reversal: A Single-Institution Experience. Surg Laparosc Endosc Percutan Tech 25:e156-8
Chen, Zhong; Lan, Xun; Thomas-Ahner, Jennifer M et al. (2015) Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J 34:502-16

Showing the most recent 10 out of 116 publications